Track topics on Twitter Track topics that are important to you
Amgen has licensed Ligand Pharmaceuticals’ Captisol ® technology for use in the formulation of AMG 330, the biotech giant’s Phase I acute myeloid leukemia candidate, through an agreement whose value was not disclosed. The companies have inked a commercial license and supply agreement that replaces an earlier research agreement that allowed Amgen to evaluate AMG 330 with Captisol in preclinical and early clinical studies. The new agreement gives Amgen exclusive worldwide rights to combine Captisol with AMG 330 in human drugs for a variety of therapeutic indications, Ligand said. AMG 330 is an anti-CD33 x anti-CD3 Bispecific T cell Engager (BiTE ® ) antibody construct. Captisol is a patent-protected, chemically modified cyclodextrin whose structure is designed to optimize the solubility and stability of drugs. “This agreement expands our license relationship with Amgen on AMG 330,” Ligand CEO John Higgins said in a statement issued yesterday. “Ligand’s ...
Original Article: Amgen Licenses Ligand's Captisol Technology for AML Candidate AMG 330NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...